tiprankstipranks
Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
US Market
IMRX
Immuneering
RESEARCH TOOLSreports
Want to see IMRX full AI Analyst Report?

Immuneering (IMRX) Earnings Dates, Call Summary & Reports

672 Followers

Earnings Data

Report Date
Aug 12, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.27
Last Year’s EPS
-0.4
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 5 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.
Company Guidance
During the Immuneering Corporation's third-quarter 2025 conference call, CEO Benjamin Zeskind highlighted notable guidance for the company's development plans, focusing on their Phase IIa trial of atebimetinib. Immuneering plans to prioritize atebimetinib in combination with gemcitabine nab-paclitaxel due to its impressive 86% overall survival rate at nine months in first-line pancreatic cancer patients, compared to the standard 47%. The company aims to present updated results at a major medical meeting in 2026. Financially, Immuneering strengthened its position with $225 million in cumulative financing, extending its cash runway into 2029, which supports the planned pivotal Phase III trials and other developments. Additionally, the company is preparing to dose the first patient in a pivotal trial in mid-2026 and has planned studies with Regeneron and Eli Lilly, indicating broad potential for atebimetinib across various cancer types.
Extraordinary Overall Survival in Pancreatic Cancer
In September, Immuneering Corporation announced 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine nab-paclitaxel, compared to approximately 47% with the standard of care.
Successful Financing and Extended Cash Runway
The company strengthened its balance sheet with $225 million in cumulative financing, including a $25 million strategic investment from Sanofi, extending the cash runway into 2029.
Positive Case Studies in Pancreatic Cancer Treatment
Noteworthy case studies demonstrated impressive responses, including complete response and conversion to surgical candidates, highlighting atebimetinib's potential in combination with FOLFIRINOX.
Patent Protection and New Collaborations
Immuneering was granted a U.S. Composition of Matter patent for atebimetinib, providing exclusivity into 2042, and announced collaborations with Eli Lilly and Regeneron for lung cancer trials.

Immuneering (IMRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

IMRX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 12, 2026
2026 (Q2)
-0.27 / -
-0.4―――
May 15, 2026
2026 (Q1)
-0.25 / -0.21
-0.4250.00% (+0.21)――
Mar 06, 2026
2025 (Q4)
-0.31 / -0.18
-0.5868.97% (+0.40)――
Nov 12, 2025
2025 (Q3)
-0.39 / -0.38
-0.4922.45% (+0.11)―
Aug 13, 2025
2025 (Q2)
-0.40 / -0.40
-0.4714.89% (+0.07)――
May 05, 2025
2025 (Q1)
-0.53 / -0.42
-0.4914.29% (+0.07)――
Mar 20, 2025
2024 (Q4)
-0.42 / -0.58
-0.52-11.54% (-0.06)――
Nov 13, 2024
2024 (Q3)
-0.55 / -0.49
-0.43-13.95% (-0.06)――
Aug 06, 2024
2024 (Q2)
-0.52 / -0.47
-0.43-9.30% (-0.04)――
May 07, 2024
2024 (Q1)
-0.50 / -0.49
-0.513.92% (+0.02)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

IMRX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 15, 2026
$5.14$5.16+0.39%
Mar 06, 2026
$4.98$5.33+7.03%
Nov 12, 2025
$6.62$6.45-2.57%
Aug 13, 2025
$3.22$3.04-5.59%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Immuneering Corp. Class A (IMRX) report earnings?
Immuneering Corp. Class A (IMRX) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
    What is Immuneering Corp. Class A (IMRX) earnings time?
    Immuneering Corp. Class A (IMRX) earnings time is at Aug 12, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is IMRX EPS forecast?
          IMRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.27.